INVO Fertility, Inc. (IVF) · Nov 4, 2026 · Other events
1-for-4 reverse split — 1-for-4 ratio; approximately 1.19M shares outstanding post-split
INVO Fertility’s reverse split is now effective, but the 8-K adds no new clinic, revenue, or strategy update beyond the previously announced share reset.
INVO is in the middle of a transition from a medical-device company into a four-clinic fertility operator, with growth supposed to come from expanding existing clinics and acquiring profitable U.S. fertility practices. Its latest quarterly filing described four U.S. clinics and a strategy centered on clinic ownership, while also noting the need for additional funding before operations generate enough cash.
This filing confirms a completed capital-structure action, not a business development. The 1-for-4 reverse split became effective on October 30, 2026, exactly as announced on October 27. 〔0〕 The company’s authorized common stock was reduced proportionally to 62.5 million shares, and options, warrants, and equity-plan reserves were adjusted accordingly. 〔1〕
The repeated share reset underscores ongoing listing and financing pressure, but this 8-K does not worsen or improve the clinic story by itself. INVO had already disclosed a 1-for-5 reverse split earlier in 2026 as part of restoring Nasdaq bid-price compliance, so the direction was known; the current filing mainly formalizes the second split and its post-split share count.
Bottom line: This is housekeeping around the share count, not progress on INVO’s fertility-clinic expansion. It matters as a reminder of capital-structure pressure, but it does not change the operating story today.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!